QDEL, US2197981051

QuidelOrtho appoints Sanjeev Sharma. QuidelOrtho stock sits 65.12 percent below its high

Published on 10/08/2026 at 22:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue reached USD 630.90 million, up 2.80 percent year over year. QuidelOrtho stock costs EUR 11.09 on October 8, 2026 after EUR 10.99.

Key points in brief

QuidelOrtho appointed Sanjeev Sharma as vice president of investor relations, effective September 28, 2026.
Second-quarter 2026 revenue reached USD 630.90 million, up 2.80 percent year over year.
The Lang & Schwarz price was EUR 11.09 on October 8, 2026, plus 0.91 percent versus EUR 10.99.
QuidelOrtho amended credit terms covering USD 1.15 billion of senior secured term loans on September 23, 2026.

QDEL, US2197981051, Illustration mit AI erstellt.

QuidelOrtho (ISIN US2197981051) was trading at EUR 11.09 at Lang & Schwarz on October 8, 2026, up 0.91 percent versus the prior close of EUR 10.99. On October 7, 2026, QuidelOrtho appointed Sanjeev Sharma as vice president of investor relations, effective September 28, 2026, and the Nasdaq-listed stock remained 65.12 percent below its 52-week high of USD 35.58. FT reported the appointment.

Three dates define the latest picture

On August 6, 2026, QuidelOrtho reported second-quarter 2026 revenue of USD 630.90 million, up 2.80 percent year over year, while adjusted earnings per share reached USD 0.13 versus a consensus loss of USD 0.05, according to MarketBeat. On September 23, 2026, QuidelOrtho amended its credit agreement, including a USD 1.15 billion senior secured term loan A facility, according to the SEC filing. The October 7 appointment added a new investor-relations executive with more than 20 years of experience, as FT reported.

What does the debt amendment change?

The September 23 amendment resets financial covenant levels through the fiscal quarter ending September 30, 2029. The initial maximum consolidated leverage ratio is 5.50 to 1.00, while the minimum consolidated interest coverage ratio is 2.25 to 1.00, according to the SEC filing. That structure gives the company covenant relief but also keeps leverage and cash generation central to the stock discussion.

Next date is November 4

MarketBeat lists November 4, 2026, as the date for QuidelOrtho's third-quarter 2026 earnings report, with consensus revenue of USD 628.08 million and consensus earnings per share of USD 0.20. Those estimates stand against second-quarter revenue of USD 630.90 million and adjusted earnings per share of USD 0.13, making the next report a direct test of operating momentum. The company operates in diagnostic testing across laboratory, transfusion medicine, point-of-care and molecular diagnostics markets.

Stock remains below its yearly high

QuidelOrtho was trading at EUR 11.09 at Lang & Schwarz on October 8, 2026, compared with EUR 10.99 at the prior close, a gain of 0.91 percent. The reference quote came from the Lang & Schwarz data set dated October 8, 2026. The further course of trading is shown by the continuously updated real-time quote of QuidelOrtho stock.